Synopsis: Thyrocare Technologies saw its stock gain after promoter Docon Technologies sold 53.33 lakh shares, reducing its holding from 70.98 percent to 60.93 percent.
A healthcare diagnostics stock edged higher today after a key promoter sold a portion of its stake in the company. The transaction, valued at approximately Rs. 667.69 crore, was conducted through market trades and will be settled as per applicable regulations.
Thyrocare Technologies Limited has a market capitalization of Rs. 6,730.29 crore. The stock opened at Rs. 1,268.70 and touched an intraday high of Rs. 1,279, marking an increase of 2.03 percent from the previous close of Rs. 1,253.30.
What’s the News?
Thyrocare Technologies received disclosures from Docon Technologies Private Limited, a promoter of the company, stating that Docon sold 53,32,860 equity shares through market trades on 24th October 2025. The total gross consideration for the sale was Rs. 667.69 crore, at an average price of approximately Rs. 1,252.03 per share.
The shares sold represent roughly 10 percent of the company’s total paid-up capital. Following this transaction, Docon continues to be a promoter, but its shareholding has reduced from 70.98 percent to 60.93 percent. Settlement of the transaction will follow applicable laws and regulations.
Financial Snapshot – Q2FY26 Results
Quarter-on-Quarter, Thyrocare Technologies reported sales rising from Rs. 193 crore to Rs. 217 crore, up 12.44 percent, while operating profit increased from Rs. 58 crore to Rs. 71 crore, a growth of 22.41 percent. Profit before tax jumped from Rs. 50 crore to Rs. 63 crore, up 26 percent, and net profit increased from Rs. 38 crore to Rs. 48 crore, up 26.32 percent.
Year-on-Year, sales grew from Rs. 177 crore to Rs. 217 crore, a rise of 22.60 percent. Operating profit increased from Rs. 48 crore to Rs. 71 crore, up 47.92 percent. PBT surged from Rs. 37 crore to Rs. 63 crore, a 70.27 percent increase, while net profit jumped from Rs. 26 crore to Rs. 48 crore, marking an impressive 84.62 percent rise.
About the Company
Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India’s first fully automated laboratory chain with a strong PAN-India presence. The company provides high-quality, affordable diagnostic services to laboratories and hospitals.
ith a quarterly active franchise network of over 10,000 and 53.3 million diagnostic investigations processed in Q2FY26, Thyrocare is widely used across India. It has earned global accreditations including ISO 9001:2015, NABL, and CAP, reflecting its commitment to quality and accuracy in diagnostics. Docon Technologies remains one of the promoters of the company following the recent share sale.
-Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Healthcare stock jumps after promoter offloads 10% stake in the company appeared first on Trade Brains.